June 15, 2011 ? 9:07 am
GlaxoSmithKline has announced that it will pay $39 million in cash to acquire the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique in the joint venture company Shenzhen GSK-Neptunus Biologicals. Established in June 2009, the alliance focuses on the development and manufacturing of seasonal and pandemic influenza vaccines for China, Hong Kong and Macau. GSK already had increased its equity share from 40% to 49% in August 2010.
fever rent socom jodie foster hot rod rebecca black scott pilgrim vs. the world
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.